The Malaria P.f/P.v Antigen Rapid Test is a lateral flow immunoassay for the qualitative detection of Histidine-Rich Protein II (HRP-II) specific to Plasmodium falciparum (P.f) and Plasmodium lactate dehydrogenase (pLDH) specific to Plasmodium vivax (P.v) in human whole blood specimen. It is intended to be used by professionals as a screening test and provides a preliminary test result to aid in the diagnosis of infection with Malaria. For professional in vitro diagnostic use only.
Introduction Malaria is one of the most devastating infectious diseases of humans. It is problematic clinically and economically as it prevails in poorer countries and regions, strongly hindering socioeconomic development. The causative agents of malaria are unicellular protozoan parasites belonging to the genus Plasmodium. These parasites infect not only humans but also other vertebrates, from reptiles and birds to mammals. The Malaria P.f/P.v Antigen Rapid Test is a rapid lateral flow immunoassay for the qualitative detection of Histidine-Rich Protein II (HRP-II) specific to Plasmodium falciparum (P.f) and Plasmodium lactate dehydrogenase (pLDH) specific to Plasmodium vivax (P.v) in human whole blood and can give a result between 20-30 minutes by minimally skilled personnel without any laboratory equipment.
Product Features
Product Name:Malaria P.f/P.v Antigen Rapid Test
Sample Type:Whole Blood
Loading Volume:2 drops
Reaction Time:20-30 mins
Shelf Life:24 months
Storage:35.6-104°F (2-40℃)
Test Procedure The test should be operated at room temperature 59-86°F (15-30℃). 1. Allow the test cassette, specimen and buffer to reach room temperature before testing. 2. Remove the test cassette from the foil pouch and use it as soon as possible. 3. Place the test cassette on a flat and clean surface. Transfer the specimen by a pipette or a dropper: 4. Wait for the colored line(s) to appear and read the results between 20-30 minutes.
The Malaria P.f/Pan Antigen Rapid Test is a rapid lateral flow immunoassay for the qualitative detection of Histidine-Rich Protein II (HRP-II) specific to Plasmodium falciparum (P.f) and Plasmodium lactate dehydrogenase (pLDH) specific to Plasmodium species (Pan) in human whole blood specimen. It is intended to be used by professionals as a screening test and provides a preliminary test result to aid in the diagnosis of infection with Malaria. For professional in vitro diagnostic use only.
Myo is the earliest marker after AMI, and it is a sensitive and accurate indicator to judge whether there is reperfusion in thrombolytic therapy. Biotime Myo test kit is mainly used to detect Myo quantity in human serum and plasma samples.
The ALL NEW FLI-100 Analyser represents an elevated standard at Biotime, in pursuing simplicity, quality assurance, and data security for healthcare organizations. Designed for quantitative in vitro assay determinations, the Biotime FLI-100 analyser was purposefully built to support immunoassay analysis for a broad range of applications – from biomarker work to infectious disease testing. The analyser’s immunofluorescence technology yields high sensitivity, reliable, and reproducible results for convenient point-of-care diagnostic testing on one device with a small footprint.
CLi-1600 semi-automated device which quantifies biomarkers for thyroid disease, inflammation, cardiac diseases, fertility, diabetes, bone metabolism, anemia, and health check by analyzing human serum, plasma and whole blood.
PRL Rapid Quantitative Test (Chemiluminescence Immunoassay) is used for in vitro quantitative detection of the Prolactin (PRL) concentration in human serum and plasma that contains heparin /EDTA and other anticoagulants samples, mainly used for auxiliary diagnosis of reproductive hormones diseases.
β-HCG is a fluorescent immunoassay for the quantitative measurement of β-HCG level in human serum and whole blood. This test is performed to help diagnose pregnancy if a woman is to undergo a medical treatment, be placed on certain drugs, or have other testing, such as x-rays, that might harm the developing baby.
FLI-600 is a fluorescent immunoassay system with 6 channels that uses blood and urine to measure the quantitative concentration of targeted analyte. Its automated test process enables to carry out multiple simultaneous tests for six different samples.
NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2, sidero- calin) is a novel biomarker for diagnosing acute kidney injury (AKI). Under normal conditions NGAL levels are low in urine and plasma Still, they rise sharply from basal levels in response to kidney injury to reach diagnostic levels within a very short time - as much as 24 hours or more before any significant rise in serum creatinine.